{
    "symbol": "BMRN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-10-26 22:05:02",
    "content": "  Turning on to our second and most recently approved of product opportunity, ROCTAVIAN, gene therapy for the treatment of hemophilia A since receiving European approval in the third quarter, we are now in the final stages of negotiating outcome-based agreements for OBAs with the key payers in Germany and with ROCTAVIAN pricing in Germany, business and labeled commercial product in our warehouse and ready to ship, we expect to treat the first patient there in the fourth quarter."
}